Adoptive Immunotherapy for B-cell Malignancies Using CD19- Targeted Chimeric Antigen Receptor T-Cells: A Systematic Review of Efficacy and Safety

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking

(2016) Friederike Braig et al.   BLOOD

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

(2016) R. Gardner et al.   BLOOD

Chimeric antigen receptor T cell therapy: 25years in the making

(2016) Saar Gill et al.   BLOOD REVIEWS

Chimeric antigen receptors: driving immunology towards synthetic biology

(2016) Michel Sadelain   CURRENT OPINION IN IMMUNOLOGY

From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain

(2016) Yanling Wu et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation

(2016) Maria-Luisa Schubert et al.   HUMAN GENE THERAPY

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

(2016) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy

(2016) Hanren Dai et al.   JNCI-Journal of the National Cancer Institute

The possible perils of targeted therapy

(2016) U Duffner et al.   LEUKEMIA

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy

(2016) Hanren Dai et al.   JNCI-Journal of the National Cancer Institute

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

(2015) S. L. Maude et al.   BLOOD

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

(2015) E. Sotillo et al.   Cancer Discovery

Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis

(2015) Tengfei Zhang et al.   Oncotarget

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

(2014) M. V. Maus et al.   BLOOD

CD19-CAR Trials

(2014) Carlos A. Ramos et al.   CANCER JOURNAL

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

(2014) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

(2013) C. R. Y. Cruz et al.   BLOOD

Simplified process for the production of anti–CD19-CAR–engineered T cells

(2013) Barbara Tumaini et al.   CYTOTHERAPY

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

(2012) M. S. Topp et al.   BLOOD

Equipping CAR-Modified T Cells with a Brake to Prevent Chronic Adverse Effects

(2012) Wei Wang et al.   CURRENT GENE THERAPY

Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

(2012) J. Scholler et al.   Science Translational Medicine

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

(2011) R. J. Brentjens et al.   BLOOD

Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation

(2011) Claire Roddie et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

(2011) Antonio Di Stasi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans

(2010) Michael C. Jensen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

(2010) J. N. Kochenderfer et al.   BLOOD

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells

(2010) J. N. Kochenderfer et al.   BLOOD

Adoptive T cell therapy of cancer

(2010) Malcolm K Brenner et al.   CURRENT OPINION IN IMMUNOLOGY

Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell

(2010) Luca Biasco et al.   EMBO Molecular Medicine

Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells

(2010) Eleanor J. Cheadle et al.   JOURNAL OF IMMUNOLOGY

Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial

(2010) Renier Brentjens et al.   MOLECULAR THERAPY

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

(2009) H. E. Heslop et al.   BLOOD

Gene modulation and immunoregulatory roles of Interferonγ

(2009) Banishree Saha et al.   CYTOKINE

Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy

(2009) Daniel Hollyman et al.   JOURNAL OF IMMUNOTHERAPY

Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor

(2009) James N. Kochenderfer et al.   JOURNAL OF IMMUNOTHERAPY